· *Gilead's stock fell 4% on Monday after a coronavirus drug trial showed mixed results in moderately ill people. *
· *The company tested the drug in patients who received the treatment for both 5 days and 10 days. *
· *Patients who received it for 5 days were 65% more likely to show signs of recovery than those who...
Gilead slides 4% after COVID-19 drug shows limited benefit in moderately ill patients
Business Insider
0 shares
1 views
You might like
Related news coverage
Gilead's remdesivir shows modest improvement in moderate COVID-19 patients
Gilead Sciences Inc on Monday reported that its antiviral drug remdesivir provided a modest benefit in patients with moderate..
Reuters